Linking chronic tryptophan deficiency with impaired bone metabolism and reduced bone accrual in growing rats

Journal of Cellular Biochemistry

Volumn 107, Issue 5, 2009, Pages 890-898

  Sibilia, Valeria ^a   Pagani, Francesca ^a   Lattuada, Norma ^a   Greco, Antonella ^a   Guidobono, Francesca ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Bone mass; Bone metabolism; Serotonin depletion; Tryptophan

Indexed keywords

BIOLOGICAL MARKER; DEOXYPYRIDINOLINE; OSTEOCALCIN; SEROTONIN; SOMATOMEDIN C;

AMINO ACID DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BODY WEIGHT; BONE DENSITY; BONE GROWTH; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE STRENGTH; CHRONIC TRYPTOPHAN DEFICIENCY; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; GROWTH REGULATION; MALE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; URINALYSIS;

ABSORPTIOMETRY, PHOTON; AMINO ACIDS; ANIMALS; BODY WEIGHT; BONE AND BONES; BONE DEVELOPMENT; BONE REMODELING; CHRONIC DISEASE; DIET; FEEDING BEHAVIOR; FEMUR; HYDROXYINDOLEACETIC ACID; INSULIN-LIKE GROWTH FACTOR I; MALE; RATS; RATS, SPRAGUE-DAWLEY; TIBIA; TOMOGRAPHY, X-RAY COMPUTED; TRYPTOPHAN;

RATTUS;

EID: 67749119864     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22189     Document Type: Article

References (43)

1. Battaglino R, Fu J, Späte U, Ersoy U, Joe M, Sedaghat L, Stashenko P. 2004. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 19:1420-1431.
2. Battaglino R, Vokes M, Schulze-Späte U, Sharma A, Graves D, Kohler T, Müller R, Yoganathan S, Stashenko P. 2007. Fluoxetine treatment increases trabecular bone formation in mice. J Cell Biochem 100:1387-1394.
3. Bell C, Abrams J, Nutt D. 2001. Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 178:399-405.
4. Bikle DD, Sakata T, Halloran BP. 2003. The impact of skeletal unloading on bone formation. Gravit Space Biol Bull 16:45-54.
5. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J. 1996. Childhood and adolescent depression: A review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry 35:1575-1583.
6. Bliziotes M, Eshleman A, Zhang XW, Wiren K. 2001. Neurotransmitter action in osteoblasts: Expression of a functional system for serotonin receptor activation and reuptake. Bone 29:477-486.
7. Bliziotes M, Eshleman A, Burt-Pichat B, Zhang XW, Hashimoto J, Wiren K, Chenu C. 2006. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 39:1313-1321.
8. Bonnet N, Bernard P, Beaupied H, Bizot JC, Trovero F, Courteix D, Benhamou CL. 2007. Various effects of antidepressant drugs on bone microarchitectecture, mechanical properties and bone remodeling. Toxicol Appl Pharmacol 221:111-118.
9. Cahir M, Ardis T, Reynolds GP, Cooper SJ. 2007. Acute and chronic tryptophan depletion differentially regulate central 5-HT1A and 5-HT 2A receptor binding in the rat. Psychopharmacology (Berl) 190:497-506.
10. Canalis E, Agnusdei D. 1996. Insulin-like growth factors and their role in osteoporosis. Calcif Tissue Int 58:133-134.
11. Chevalley T, Strong DD, Mohan S, Baylink D, Linkhart TA. 1996. Evidence for a role for insulin-like growth factor binding proteins in glucocorticoid inhibition of normal human osteoblast-like cell proliferation. Eur J Endocrinol 134:591-601.
12. Cizza G, Ravn P, Chrousos GP, Gold PW. 2001. Depression: A major, unrecognized risk factor for osteoporosis? Trends Endocrinol Metab 12:198-203.
13. Collet C, Schiltz C, Geoffroy V, Maroteaux L, Launay JM, de Vernejoul MC. 2008. The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J 22:418-427.
14. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, Ensrud KE. 2007. Use of antidepressants and rates of hip bone loss in older women: The study of osteoporotic fractures. Arch Intern Med 167:1240-1245.
15. D'Souza DN, Zhang Y, Garcia F, Battaglia G, Van de Kar LD. 2004. Fluoxetine-induced changes in body weight and 5-HT1A receptor-mediated hormone secretion in rats on a tryptophan-deficient diet. Am J Physiol Regul Integr Comp Physiol 286:R390-R397.
16. Dufour C, Holy X, Marie PJ. 2007. Skeletal unloading induces osteoblast apoptosis and targets alpha5beta1-PI3K-Bcl-2 signaling in rat bone. Exp Cell Res 313:394-403.
17. Gala Paniagua J, Díaz-Curiel M, de la Piedra Gordo C, Castilla Reparaz C, Torralbo García M. 1998. Bone mass assessment in rats by dual energy X-ray absorptiometry. Br J Radiol 71:754-758.
18. Giustina A, Mazziotti G, Canalis E. 2008. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535-559.
19. Gustafsson BI, Thommesen L, Stunes AK, Tommeras K, Westbroek I, Waldum HL, Slørdahl K, Tamburstuen MV, Reseland JE, Syversen U. 2006a. Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 98:139-151.
20. Gustafsson BI, Westbroek I, Waarsing JH, Waldum H, Solligård E, Brunsvik A, Dimmen S, van Leeuwen JP, Weinans H, Syversen U. 2006b. Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. J Cell Biochem 97:1283-1291.
21. Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, Orwoll E, Bliziotes MM, the Osteoporotic Fractures in Men Study Group. 2007. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167:1246-1251.
22. Harel Z. 2008. Bone metabolism during adolescence: The known, the unknown, and the controversial. Adolesc Med State Art Rev 19:573-591.
23. Harp JB, Goldstein S, Phillips LS. 1991. Nutrition and somatomedin. XXIII. Molecular regulation of IGF-I by amino acid availability in cultured hepatocytes. Diabetes 40:95-101.
24. Jonnakuty C, Gragnoli C. 2008. What do we know about serotonin? J Cell Physiol 217:301-306.
25. Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP. 2002. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: An in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27:949-959.
26. Murphy DL, Lesch KP. 2008. Targeting the murine serotonin transporter: Insights into human neurobiology. Nat Rev Neurosci 9:85-96.
27. Ni YG, Miledi R. 1997. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA 94:2036-2040.
28. Ortoft G, Andreassen TT, Oxlund H. 1999. Growth hormone increases cortical and cancellous bone mass in young growing rats with glucocorticoid-induced osteopenia. J Bone Miner Res 14:710-721.
29. Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J. 1996. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology 126:234-240.
30. Rosen CJ. 1994. Growth hormone, insulin-like growth factors, and the senescent skeleton: Ponce de Leon's Fountain revisited? J Cell Biochem 56:348-356.
31. Rosen CJ. 2009. Serotonin rising - The bone, brain, bowel connection. N Engl J Med 360:957-959.
32. Rosen CJ, Donahue LR. 1995. Insulin like growth factors: Potential therapeutic options for osteoporosis. Trends Endocrinol Metab 6:235-240.
33. Thissen JP, Triest S, Moats-Staats BM, Underwood LE, Mauerhoff T, Maiter D, Ketelslegers JM. 1991. Evidence that pretranslational and translational defects decrease serum insulin-like growth factor-I concentrations during dietary protein restriction. Endocrinology 129:429-435.
34. Thissen JP, Davenport ML, Pucilowska JB, Miles MV, Underwood LE. 1992. Increased serum clearance and degradation of 125I-labeled IGF-I in protein-restricted rats. Am J Physiol 262:E406-E411.
35. Thissen JP, Pucilowska JB, Underwood LE. 1994. Differential regulation of insulin-like growth factor I (IGF-I) and IGF binding protein-1 messenger ribonucleic acids by amino acid availability and growth hormone in rat hepatocyte primary culture. Endocrinology 134:1570-1576.
36. VandeHaar MJ, Moats-Staats BM, Davenport ML, Walker JL, Ketelslegers JM, Sharma BK, Underwood LE. 1991. Reduced serum concentrations of insulin-like growth factor-I (IGF-I) in protein-restricted growing rats are accompanied by reduced IGF-I mRNA levels in liver and skeletal muscle. J Endocrinol 130:305-312.
37. Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH. 2005. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146:685-693.
38. Warden SJ, Nelson IR, Fuchs RK, Bliziotes MM, Turner CH. 2008. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause 15:1176-1183.
39. Westbroek I, van der Plas A, de Rooij KE, Klein-Nulend J, Nijweide PJ. 2001. Expression of serotonin receptors in bone. J Biol Chem 276:28961-28968.
40. Westbroek I, Waarsing JH, van Leeuwen JP, Waldum H, Reseland JE, Weinans H, Syversen U, Gustafsson BI. 2007. Long-term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats. J Cell Biochem 101:360-368.
41. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G. 2008. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825-837.
42. Yirmiya R, Goshen I, Bajayo A, Kreisel T, Feldman S, Tam J, Trembovler V, Csernus V, Shohami E, Bab I. 2006. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci USA 103:16876-16881.
43. Zhang P, Yokota H. 2007. Effects of surgical holes in mouse tibiae on bone formation induced by knee loading. Bone 40:1320-1328.